Skip to main content

Products

 Our Products

Welcome to Vera Pharmaceuticals' product portfolio, where we offer a diverse range of high-quality pharmaceutical solutions supported by our extensive expertise and state-of-the-art manufacturing facilities. Our commitment to innovation, quality, and safety drives us to deliver exceptional products that meet the needs of our global customers.


Active Pharmaceutical Ingredients (API)


Overview

Our API offering is backed by our network of GMP-compliant commercial manufacturing facilities located in Europe and North America. This global infrastructure allows us to meet your product requirements with the highest standards of quality and compliance. We specialize in the development and production of complex APIs, ensuring reliability and efficiency in every batch.


Key Features

- Global Manufacturing Network: Facilities in Europe and North America ensure a robust supply chain.

- GMP Compliance: Adherence to Good Manufacturing Practices guarantees the highest quality standards.

- Expertise: Decades of experience in API development and production.


Controlled Substances


Overview

Vera Pharmaceuticals has over 50 years of expertise in the development and supply of controlled substance APIs, including opioids. Our extensive range of controlled substances is produced in our GMP-compliant bulk production plants, ensuring security and reliability of supply. We understand the broad regulatory requirements and maintain excellent relationships with governing agencies such as the US Drug Enforcement Agency.


Key Features

- Extensive Range: A comprehensive portfolio of controlled substances and opioids.

- Global Facilities: Macfarlan Smith Ltd in Edinburgh, UK, and US-based facilities in West Deptford, NJ, and Devens, MA.

- Regulatory Expertise: In-depth understanding of regulatory requirements for controlled substances.

- Specialized Products: Expertise in cannabinoids, synthetic stimulants, and complex APIs.


Macfarlan Smith Ltd

Our heritage includes Macfarlan Smith Ltd, the world’s leading manufacturer of opiate alkaloids, based in Edinburgh, UK. This legacy underscores our commitment to excellence and our position as a leader in the production of controlled substances.


Bitrex®

Overview

Discovered by Verapharms, Bitrex is the most bitter substance known to man, recognized globally for its role in preventing accidental poisoning. Bitrex is inert and odourless, making it an ideal additive to render potentially harmful products extremely unpalatable without altering their original properties. It has become one of the world's leading safety components to reduce accidental poisoning, particularly among children.


Key Features

- Safety Component: Helps prevent children from swallowing harmful products by making them extremely bitter.

- Effective: Very low concentrations are sufficient to make products unpalatable.

- Versatile: Can be added to a wide range of products including household items, personal care products, autocare products, and pesticides.

- Global Impact: Recognized and used worldwide to enhance product safety.


Child Safety

Child poisoning is a significant concern, with many incidents involving young children who are particularly sensitive to bitter tastes. Bitrex acts as an effective deterrent, helping to prevent accidental ingestion of harmful household products. For example, in the UK, 25,500 children under the age of five were sent to hospital with suspected poisoning in 2013 alone.


Applications

Since its discovery in 1958, Bitrex has been developed for use in many applications, making homes safer around the world. It continues to be a critical component in products designed to protect children from accidental poisoning.

At Vera Pharmaceuticals, we are dedicated to advancing global healthcare through our innovative products and solutions. Our commitment to quality, safety, and regulatory compliance ensures that our products meet the highest standards, delivering peace of mind to our customers and improving patient outcomes worldwide.

Contact us today to learn more about our product offerings and how we can support your pharmaceutical needs.

Popular posts from this blog

Polymorph, Salt & Cocrystal Screening

 Selecting the optimal solid form of an API during early drug development can mitigate the risk of failure later in development. This can be achieved through polymorph, salt and cocrystal screening. Polymorph screening  aims to identify all relevant forms of an API, investigate their properties and choose the optimal crystalline form. Polymorphism control is exceptionally important and conducting these screens can help prevent the appearance of new forms in the latter stages of development. We focus on establishing the interconversions between forms, the relative stability of forms and understanding the monotropic or enantiotropic relationship between polymorphs when required. Polymorph screening is a regulatory requirement whether a salt, cocrystal or free form compound is chosen for development. Salt screening  is an approach to quickly identify and assess the salt forms of an API. This allows drug developers to modify the physical properties of an API while preserving ...
Read more

Crystallization Development

  Developing a robust crystallization process to isolate the optimal solid form of an API is an essential step in API development. Identifying the crystallization approach, solvent system(s), controlling form, crystal habit and delivering a consistent uniform PSD from a single process step can be very challenging. Applying expertise in, solid state, PAT and computational modelling all underpin our development of crystallization processes, allowing us to deliver the best outcome at the required scale. We also work on remediating existing crystallizations, which can have a variety of issues such as oiling out, isolating the wrong polymorphic form or just long filtration times. Understanding the crystallization behaviour of a molecule can help: Maximise process yields Improve purity Control form, morphology and particle size distribution Create processes suitable for transfer and scale-up Strengthen IP The key to controlled, growth-dominated crystallization is a thorough understanding...
Read more

Process development

  Our scientists and engineers develop synthetic processes to enable rapid, phase-appropriate product development and commercialization. Our team has expertise in synthetic organic chemistry, physical organic chemistry and particle engineering. We also have expertise in chromatographic separations from analytical to commercial scale purification. Our commitment to state-of-the-art development utilizes a wide array of equipment and tools: Reaction kinetics modelling In-line reaction monitoring and particle visualization Flow-chemistry from bench to commercial scale Chemistry automation using Mettler-Toledo Easymax and Optimax systems Process optimization and criticality determination using advanced DoE modelling HPAPI development Thermal hazard assessment utilizing Mettler Toledo RC-1
Read more